India, Aug. 11 -- PDS Biotechnology Corporation (PDSB), a late-stage immunotherapy company focused on developing targeted cancer therapies, announced a strategic refocus of its development portfolio, with investors focusing on the advancement of PDS0301 in metastatic colorectal cancer (mCRC) and the company's plans to seek strategic partnerships for PDS0101.
PDS Biotechnology is scheduled to report its second-quarter 2026 financial results on August 13, 2026.
Recent Business & Clinical Updates:
PDS Biotech said it will prioritize PDS0301, its tumor-targeted immunocytokine, following a comprehensive review of its development portfolio, capital allocation priorities and long-term strategy.
The company said Phase 2 data in metastatic micro...